title: Docetaxel in castration-resistant prostate cancer: a single-centre experience.
abstract: We present a single-institution experience reporting the efficacy and safety of docetaxel, administered as first-line chemotherapy, in castration-resistant prostate cancer (CRPC), focusing on patients and treatment parameters. From November 2004 to January 2012, 51 patients received chemotherapy with docetaxel. With a mean follow-up time (from the beginning of CHT) of 1.6 years (range 0.1-5.1 years), 35 patients (68.6%) died for prostate cancer and 48 patients (94.1%) showed progression of the disease. Five factors influenced overall survival: nodal status at diagnosis, neoadjuvant hormonal therapy, number of cycles of docetaxel administered, schedule of docetaxel and ECOG performance status before starting chemotherapy.
authors.forename: Beatrice
authors.initials: B
authors.lastname: Detti
authors.affiliation: Department of Radiation-Oncology, University of Florence, Florence, Italy,1.
authors.forename: Detti
authors.initials: D
authors.lastname: Beatrice
authors.forename: Davide
authors.initials: D
authors.lastname: Franceschini
authors.forename: Franceschini
authors.initials: F
authors.lastname: Davide
authors.forename: Calogero
authors.initials: C
authors.lastname: Saieva
authors.forename: Saieva
authors.initials: S
authors.lastname: Calogero
authors.forename: Lucia
authors.initials: L
authors.lastname: Di Brina
authors.forename: Di Brina
authors.initials: DB
authors.lastname: Lucia
authors.forename: Mohammed
authors.initials: M
authors.lastname: Baki
authors.forename: Baki
authors.initials: B
authors.lastname: Mohammed
authors.forename: Icro
authors.initials: I
authors.lastname: Meattini
authors.forename: Meattini
authors.initials: M
authors.lastname: Icro
authors.forename: Vanessa
authors.initials: V
authors.lastname: Di Cataldo
authors.forename: Di Cataldo
authors.initials: DC
authors.lastname: Vanessa
authors.forename: Eleonora Monteleone
authors.initials: EM
authors.lastname: Pasquetti
authors.forename: Monteleone Pasquetti
authors.initials: MP
authors.lastname: Eleonora
authors.forename: Ilaria
authors.initials: I
authors.lastname: Furfaro
authors.forename: Furfaro
authors.initials: F
authors.lastname: Ilaria
authors.forename: Anna
authors.initials: A
authors.lastname: Mancuso
authors.forename: Mancuso
authors.initials: M
authors.lastname: Anna
authors.forename: Gabriele
authors.initials: G
authors.lastname: Simontacchi
authors.forename: Simontacchi
authors.initials: S
authors.lastname: Gabriele
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Livi
authors.forename: Livi
authors.initials: L
authors.lastname: Lorenzo
mesh_terms: D061605:Administration, Intravenous; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005221:Fatigue / Q000139:chemically induced; D006801:Humans; D053208:Kaplan-Meier Estimate; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care / Q000706:statistics & numerical data; D016016:Proportional Hazards Models; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel
keywords: Bladder; Chemotherapy; Prostate cancer; Therapy